1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 27

    Next generation product aerosol bubbled extracts show little to no effect in high content screening endpoints when compared to cigarette smoke bubbled extracts

    TRELLES STICKEN E.(1); WIECZOREK R.(1); BODE L.M.(1); SIMMS L.(2); STEVENSON M.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), BioToxLab, Hamburg, Germany; (2) Imperial Tobacco Limited, In vitro Research, Bristol, U.K.
    Tobacco-based and tobacco-free next generation products (NGPs) are understood to be a less harmful alternative to conventional combustible cigarettes. The objective of this study was to compare the in vitro biological response of cigarette smoke...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 37

    Use of cell media nicotine concentration as a marker to predict cells surface deposited nicotine in transwells after fresh smoke/aerosol exposure

    WIECZOREK R.(1); TRELLES STICKEN E.(1); BODE L.M.(1); SIMMS l.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    Exposure of organotypic 3D lung models at the air liquid interface (ALI) to fresh whole smoke/aerosol provides a more human relevant exposure assessment of combustible cigarettes and e-vapour products. The aim of this study is to present a method...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “Toxicity Testing in the 21st Century: A Vision and a Strategy”, Fontem Ventures B.V. have investigated the utility of a series of...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 22

    Dosimetry: TPM and nicotine delivery of combusted tobacco products to the 24 and 96 Multi Well Plate and inserts on Smoke Aerosol Exposure In Vitro System (SAEIVS)

    WIECZOREK R.(1); TRELLES STICKEN E.(1); BODE L.M.(1); SIMMS L.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    In vitro exposure systems are key tools for the risk assessment of emerging electronic nicotine delivery systems as well as for conventional tobacco products. The Smoke Aerosol Exposure in vitro System (SAEIVS) used at Imperial Tobacco Limited is...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 23

    Dosimetry: the effects of cigarette smoke dilution on nicotine delivery in a 24 and 96 well format using Smoke Aerosol Exposure In Vitro System (SAEIVS)

    BODE L.M.(1); ROEWER K.(1); OTTE S.(1); WIECZOREK R.(1); SIMMS L.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    In vitro aerosol exposure systems are useful tools for screening of potential toxic effects of freshly generated smoke of conventional cigarettes[1]. An in house platform “Smoke Aerosol Exposure In Vitro System (SAEIVS)” (assembled by Burghart...
  6. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 32

    Cellular transformation activity of different tobacco condensates in the Bhas 42 cell assay

    STEVENSON M.(1); WIECZOREK R.(2); SIMMS L.(1); PANT K.(3)
    (1) Imperial Tobacco Limited, Bristol, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (3) BioReliance, Sigma-Aldrich Corp., Rockville, MD, U.S.A.
    Carcinogenesis has been described as a multi-stage process comprising of initiation, promotion and progression. Smoking is a cause of serious disease in smokers, including lung cancer. Determining the carcinogenic potential of a tobacco product...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2013, Seville, STPOST 03

    Analytical method to model human mouth-level transfer of ingredients from Swedish pouched snus

    GRAPTON S. (1); GADOIS-POMMEREUL S.(1); TROUDE V.(1); BLANCHET M. (1); CLARKE A.(2); SIMMS L.(2)
    (1) SEITA, Imperial Tobacco Group, Fleury-les-Aubrais, France; (2) Imperial Tobacco Limited, Bristol, U.K.
    In parallel with the human study[1] a laboratory in vitro assay was conducted with three media: artificial saliva, water and 1% ß-cyclodextrin in water, using two snus products that were indistinguishable apart from the flavour application rate. To...